Table 1.
Cohort demographics and clinical characteristics.
| Factor | N | Summary |
|---|---|---|
| Gender | 62 | |
| • Female | 24 [38.7] | |
| Race | 62 | |
| • Caucasian | 57 [91.9] | |
| • Hispanic | 3 [4.8] | |
| • African American | 1 [1.6] | |
| • Other | 1 [1.6] | |
| Family history | ||
| • UC | 61 | 12 [19.7] |
| • CD | 61 | 6 [9.8] |
| Smoking | 59 | |
| • Never | 58 [98.3] | |
| • Current | 1 [1.7] | |
| Age at diagnosis | 62 | 12.9 [10.8, 15.5] |
| EIM [non-exclusive] | 62 | |
| • Any EIM | 32 [51.6] | |
| • Joint | 6 [9.7] | |
| • Anaemia | 26 [41.9] | |
| Disease extent of colitis | ||
| • Extensive colitis | 59 | 59 [100] |
| Backwash ileitis present | 61 | 13 [21.3] |
| Medications prior to colectomy | ||
| • Immunomodulators [at any time] | 58 | 44 [75.9] |
| • Duration of immunomodulators [mo] | 8.0 [3.0, 22.0] | |
| • Anti-TNF [at any time] | 57 | 37 [64.9] |
| • Duration of anti-TNF [mo] | 8.5 [1.0, 18.2] | |
| • Vedolizumab [at any time] | 23 | 1 [4.4] |
| • Duration of vedolizumab [mo] | 1 | |
| Disease duration at colectomy [years] | 62 | 2.6 [0.9, 4.8] |
| Reason for colectomy | ||
| • Refractory disease | 62 | 65 [100.0] |
| Medications at time of colectomy | 62 | |
| • 6MP | 6 [9.7] | |
| • AZA | 7 [11.3] | |
| • MTX | 9 [14.5] | |
| • Anti-TNF | 14 [22.6] | |
| Length of colorectum specimen [cm] | 62 | 70.3 ± 18.5 |
| Rectum included | 62 | 24 [38.7] |
| Post-colectomy follow-up [mo] | 62 | 1.0 [1.0, 2.0] |
Values presented as mean ± standard deviation [SD], median [P25, P75], or N [column %].
CD, Crohn’s disease; UC, ulcerative colitis; EIM, extraintestinal manifestations; 6MP, mercaptopurine; AZA, azathioprine; MTX, methotrexate; TNF, tumour necrosis factor; mo, months; P, percentile.